Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of nab-paclitaxel with or without oral azacitidine in chemotherapy-naive metastatic melanoma
2013-002291-41Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Nov 2013
- Modality
- Small Molecules, Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing Abraxane monotherapy with Abraxane + CC-486 combination (2 arms). Primary endpoint: Progression-free survival. Started Nov 2013; status: terminated.
02
Drugs
nab-paclitaxelCC-486
03
Conditions
melanoma
Beyond the preview
Go deeper on 2013-002291-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002291-41.